Natriuresis-guided diuretic therapy in acute heart failure

On-site diagnosis and treatment monitoring

Acute Heart Failure (AHF) is a critical condition that requires urgent medical attention and continuous close monitoring, especially for elderly people. With symptoms ranging from breathlessness and fatigue to high jugular venous pressure and low urine output, AHF requires immediate evaluation and treatment. Approximately one million patients in Europe are hospitalized for AHF each year, requiring frequent and accurate monitoring of urinary biomarkers to guide diuretic therapy and prevent further deterioration. Current methods, which involve infrequent and delayed urine testing, often fail to reflect real-time patient conditions, leading to suboptimal treatment adjustments and increased risk of mortality and rehospitalization.

This approach facilitates early detection of poor diuretic response, allowing timely and precise adjustments to treatment plans, thereby minimizing the risk of kidney damage and improving patient outcomes. With approximately 1.73 million AHF hospitalizations annually in key markets, there is a significant opportunity to improve patient care and reduce mortality rates through the adoption of advanced urine monitoring technologies.